Patents by Inventor Helen Connaris
Helen Connaris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115659Abstract: Both Sp2CBMTD and Vc2CBMTD were shown to reduce the apical viral load of RSV-infected human airway epithelial cells. The degree of reduction was dependent on the type of mCBM and number of doses administered. Exposure of infected MucilAlr inserts to Sp2CBMTD did not show a significant effect on viral replication due to variability of data but a slight reduction was observed at the highest dose (100 ?g) after two doses at 48 h p.i (see FIG. 23A), and after three doses at 96 h p.i. compared to virus infected control. Exposure to Vc2CBMTD (100 ?g) was more effective in reducing RSV viral replication in both dosing regimens than using a 10 ?g dosing regimen. Although not statistically significant, the reduction of viral load at 48 h p.i was observed to decreased greater than 1 log (FIG. 23B).Type: ApplicationFiled: October 12, 2023Publication date: April 11, 2024Inventors: Helen Connaris, Lei Yang, Jane Alexandra Potter
-
Patent number: 11819534Abstract: The disclosure provides molecules for use in compositions, medicaments and methods for the treatment or prevention of RSV infections, its symptoms and associated pathologies and potentially infections caused or contributed to by viral pathogens which do not bind or do not primarily bind sialic acid containing receptors during pathogenesis. Specifically, the disclosure is based on the finding that molecules with affinity for (or an ability to bind to) sialic acid (and in particular sialoglycoconjugates) on cell surfaces (these including sialic acid containing glycoproteins and cell surface sialic acid receptors), find utility in the treatment and/or prevention of symptoms, infections, diseases and/or conditions associated with respiratory syncytial vims (RSV).Type: GrantFiled: February 27, 2019Date of Patent: November 21, 2023Assignee: Pneumagen LtdInventors: Helen Connaris, Lei Yang, Jane Alexandra Potter
-
Publication number: 20230125561Abstract: Disclosed are molecules useful in the treatment or prevention of viral infections in humans and animals and/or the treatment or prevention of the associated symptoms, diseases and/or conditions. The disclosure provides molecules which comprise sugar (carbohydrate/polysaccharide/sialic acid/glycan)-binding protein(s) which are useful in the treatment or prevention of Coronavirus infections and/or diseases, symptoms and/or conditions caused or contributed to by the same.Type: ApplicationFiled: March 4, 2021Publication date: April 27, 2023Inventors: Garry Taylor, Helen Connaris, Jane Potter, Graeme Rogers, Angus Aitken, Antoni Tortajada, Douglas Thomson, Lei Yang
-
Publication number: 20230054093Abstract: Disclosed are molecules with affinity for (or an ability to bind to) sialic acid (and in particular sialoglycoconjugates) on cell surfaces (these including sialic acid containing glycoproteins and cell surface sialic acid receptors), for use in treating or preventing of inflammatory diseases and/or conditions with an inflammatory aeitiology. The disclosed molecules may be of particular use in the treatment and/or prevention of diseases and/or conditions characterised by inflammation occurring as a consequence of a cascade of cytokines, inflammation that may occur in and around the tissues and/or structures of the lung and inflammation occurring as a result of an infection.Type: ApplicationFiled: August 28, 2020Publication date: February 23, 2023Inventors: Helen Connaris, Lei Yang, Jane Alexandra Potter
-
Publication number: 20230036052Abstract: The present disclosure a cohort of sialic acid binding molecules which comprise one or more modified carbohydrate binding modules (CBMs). The modified CBMs reduce the risk of adverse events related to the host immune response and/or the production of anti-drug antibodies (ADAs). The modified CBMs can be used in therapy or as medicaments and find specific application as molecules for the modulation of an immune response and/or cell growth. The modified CBMs may also be used as adjuvants, for example mucosal adjuvants and in the treatment and/or prevention of cancer, sepsis and/or diseases caused or contributed to by a pathogen that binds cell surface sialic acid-containing receptors.Type: ApplicationFiled: September 6, 2022Publication date: February 2, 2023Inventors: Helen Connaris, Jane Alexandra Potter
-
Patent number: 11466059Abstract: The present disclosure a cohort of sialic acid binding molecules which comprise one or more modified carbohydrate binding modules (CBMs). The modified CBMs reduce the risk of adverse events related to the host immune response and/or the production of anti-drug antibodies (ADAs). The modified CBMs can be used in therapy or as medicaments and find specific application as molecules for the modulation of an immune response and/or cell growth. The modified CBMs may also be used as adjuvants, for example mucosal adjuvants and in the treatment and/or prevention of cancer, sepsis and/or diseases caused or contributed to by a pathogen that binds cell surface sialic acid-containing receptors.Type: GrantFiled: January 9, 2019Date of Patent: October 11, 2022Assignee: Pneumagen LtdInventors: Helen Connaris, Jane Alexandra Potter
-
Patent number: 11406704Abstract: The present disclosure provides novel adjuvants which may be used in combination with one or more antigens to augment, modulate or enhance a host immune response to the one or more antigens. The adjuvants are based on sialic acid binding molecules and may be combined with any type of antigen. The adjuvants may be formulated for mucosal and/or intranasal administration.Type: GrantFiled: September 20, 2017Date of Patent: August 9, 2022Assignee: PNEUMAGEN LIMITEDInventors: Helen Connaris, Garry Taylor, Richard E. Randall
-
Patent number: 11389502Abstract: The present disclosure provides molecules which modulate cell growth. These molecules include those that bind sialic acid which may find application in the treatment and/or prevention of cell proliferation and/or differentiation disorders, cancer and/or it's migration and/or spread.Type: GrantFiled: September 20, 2017Date of Patent: July 19, 2022Assignee: OMIDEON LIMITEDInventors: Helen Connaris, Judith Telford, Graeme Rogers
-
Publication number: 20220088120Abstract: The present disclosure provides molecules which modulate cell growth. These molecules include those that bind carbohydrates and may find application in the treatment and/or prevention of cell proliferation and/or differentiation disorders, cancer and/or it's migration and/or spread.Type: ApplicationFiled: January 24, 2020Publication date: March 24, 2022Inventors: Graeme Rogers, Helen Connaris
-
Publication number: 20220031816Abstract: The present disclosure provides molecules which modulate cell growth and which have utility in the treatment of certain cancers and as a delivery system for heterologous molecules. The disclosed molecules can also be used to modulate the expression, function and/or activity of certain classes of gene.Type: ApplicationFiled: December 6, 2019Publication date: February 3, 2022Inventors: Helen Connaris, Graeme Rogers
-
Patent number: 10953078Abstract: The disclosure provides molecules with an affinity for (or an ability to bind to), sialic acid, for use in compositions, medicaments and methods for the treatment of sepsis, its symptoms and sepsis associated pathologies and immune responses.Type: GrantFiled: September 20, 2017Date of Patent: March 23, 2021Assignee: Pneumagen LimitedInventors: Helen Connaris, Garry Taylor, Hasan Yesilkaya, Peter Andrew
-
Publication number: 20210070814Abstract: The present disclosure a cohort of sialic acid binding molecules which comprise one or more modified carbohydrate binding modules (CBMs). The modified CBMs reduce the risk of adverse events related to the host immune response and/or the production of anti-drug antibodies (ADAs). The modified CBMs can be used in therapy or as medicaments and find specific application as molecules for the modulation of an immune response and/or cell growth. The modified CBMs may also be used as adjuvants, for example mucosal adjuvants and in the treatment and/or prevention of cancer, sepsis and/or diseases caused or contributed to by a pathogen that binds cell surface sialic acid-containing receptors.Type: ApplicationFiled: January 9, 2019Publication date: March 11, 2021Inventors: Helen Connaris, Jane Alexandra Potter
-
Publication number: 20200390851Abstract: The disclosure provides molecules for use in compositions, medicaments and methods for the treatment or prevention of RSV infections, its symptoms and associated pathologies and potentially infections caused or contributed to by viral pathogens which do not bind or do not primarily bind sialic acid containing receptors during pathogenesis. Specifically, the disclosure is based on the finding that molecules with affinity for (or an ability to bind to) sialic acid (and in particular sialoglycoconjugates) on cell surfaces (these including sialic acid containing glycoproteins and cell surface sialic acid receptors), find utility in the treatment and/or prevention of symptoms, infections, diseases and/or conditions associated with respiratory syncytial virus (RSV).Type: ApplicationFiled: February 27, 2019Publication date: December 17, 2020Inventors: Helen Connaris, Lei Yang, Jane Alexandra Potter
-
Publication number: 20190247460Abstract: The present disclosure provides molecules which modulate cell growth. These molecules include those that bind sialic acid which may find application in the treatment and/or prevention of cell proliferation and/or differentiation disorders, cancer and/or it's migration and/or spread.Type: ApplicationFiled: September 20, 2017Publication date: August 15, 2019Inventors: Helen Connaris, Judith Telford, Graeme Rogers
-
Publication number: 20190231853Abstract: The disclosure provides molecules with an affinity for (or an ability to bind to), sialic acid, for use in compositions, medicaments and methods for the treatment of sepsis, its symptoms and sepsis associated pathologies and immune responses.Type: ApplicationFiled: September 20, 2017Publication date: August 1, 2019Inventors: Helen Connaris, Garry Taylor, Hasan Yesilkaya, Peter Andrew
-
Patent number: 10363298Abstract: The present invention is based on the finding that in addition to interfering with or blocking, preventing and/or inhibiting the interaction between a pathogen and, for example, a sialic acid containing cell surface receptor, certain sialic acid binding molecules have immunomodulatory properties. The invention provides methods and uses which exploit sialic acid binding molecules in the treatment and/or prevention of disease by modulation and/or priming of the host immune response.Type: GrantFiled: January 23, 2015Date of Patent: July 30, 2019Assignee: University Court of the University of St. AndrewsInventors: Garry Taylor, Helen Connaris
-
Publication number: 20190224311Abstract: The present disclosure provides novel adjuvants which may be used in combination with one or more antigens to augment, modulate or enhance a host immune response to the one or more antigens. The adjuvants are based on sialic acid binding molecules and may be combined with any type of antigen. The adjuvants may be formulated for mucosal and/or intranasal administration.Type: ApplicationFiled: September 20, 2017Publication date: July 25, 2019Inventors: Helen Connaris, Garry Taylor, Richard E. Randall
-
Publication number: 20170007692Abstract: The present invention is based on the finding that in addition to interfering with or blocking, preventing and/or inhibiting the interaction between a pathogen and, for example, a sialic acid containing cell surface receptor, certain sialic acid binding molecules have immunomodulatory properties. The invention provides methods and uses which exploit sialic acid binding molecules in the treatment and/or prevention of disease by modulation and/or priming of the host immune response.Type: ApplicationFiled: January 23, 2015Publication date: January 12, 2017Inventors: Garry Taylor, Helen Connaris
-
Patent number: 9066894Abstract: The present invention provides compounds, compositions, medicaments and methods comprising or using carbohydrate binding molecules. More specifically, the invention provides a means of treating diseases and/or conditions caused or contributed to by pathogens, particularly microbial pathogens and methods of screening, identifying, detecting tagging and/or labelling carbohydrates.Type: GrantFiled: September 11, 2009Date of Patent: June 30, 2015Assignee: UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWSInventors: Helen Connaris, Garry Taylor
-
Publication number: 20110269670Abstract: The present invention provides compounds, compositions, medicaments and methods comprising or using carbohydrate binding molecules. More specifically, the invention provides a means of treating diseases and/or conditions caused or contributed to by pathogens, particularly microbial pathogens and methods of screening, identifying, detecting tagging and/or labelling carbohydrates.Type: ApplicationFiled: September 11, 2009Publication date: November 3, 2011Inventors: Helen Connaris, Garry Taylor